Environmental

Sana Biotechnology’s environmental profile is broadly neutral versus peers because disclosed metrics provide little evidence of differentiated emissions, energy, or resource-management performance.

Zero reported R&D intensity in the supplied metrics limits environmental inference, but it also prevents evidence of a peer-leading low-carbon operating footprint.

The company’s likely laboratory and manufacturing footprint creates typical biotech utility and materials exposure, yet no disclosed data indicate materially worse environmental risk than peers.

Compared with larger biopharma peers that often publish more detailed climate targets and operational disclosures, Sana appears less transparent rather than clearly stronger or weaker.

Social

Sana’s social positioning is constrained by limited disclosure, which weakens comparability versus peers that report more robust workforce, safety, and access metrics.

The absence of stock-based compensation in the supplied data suggests limited dilution pressure, but it does not by itself demonstrate stronger employee-alignment practices than peers.

As a cell-therapy developer, the company faces inherent patient-safety and trial-conduct expectations, yet no disclosed controversies indicate a materially worse social profile than peers.

Relative to better-disclosed biotech peers, Sana appears average on social transparency and unproven on broader stakeholder outcomes.

Governance

Governance appears somewhat better than many early-stage biotech peers because the supplied leverage metrics show modest debt and negative net debt, reducing creditor-driven governance pressure.

The zero stock-based compensation metric in the provided data suggests less compensation-related dilution than peers, supporting a cleaner capital-allocation profile.

However, limited disclosure on board independence, executive incentives, and compliance controls prevents Sana from ranking as a strong governance leader versus more mature peers.

Overall governance is supported by a relatively conservative balance-sheet signal, but peer-relative transparency remains insufficient for a higher score.

Overall Score

Sana Biotechnology’s ESG positioning is broadly average versus peers, with modest governance support offset by limited disclosure across environmental and social dimensions.

Score Driver: Limited ESG Disclosure Versus Peers